These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36874115)

  • 1. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
    Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
    Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.
    Gan L; Lang M; Tian X; Ren S; Li G; Liu Y; Han R; Zhu K; Li H; Wu Q; Cui Y; Zhang W; Fang F; Li Q; Song T
    J Hepatocell Carcinoma; 2023; 10():673-686. PubMed ID: 37125392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
    Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
    Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
    Wang X; Sun X; Lei Y; Fang L; Wang Y; Feng K; Xia F
    BMC Cancer; 2024 Aug; 24(1):1036. PubMed ID: 39174912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.
    Cao F; Yang Y; Si T; Luo J; Zeng H; Zhang Z; Feng D; Chen Y; Zheng J
    Front Oncol; 2021; 11():783480. PubMed ID: 34988019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of radiotherapy combined with lenvatinib plus PD-1 inhibitors as neo-adjuvant therapy in hepatocellular carcinoma with portal vein thrombus: protocol of an open-label, single-arm, prospective, multi-center phase I trial.
    Li G; Shu B; Zheng Z; Yin H; Zhang C; Xiao Y; Yang Y; Yan Z; Zhang X; Yang S; Li G; Dong J
    Front Oncol; 2022; 12():1051916. PubMed ID: 36505833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma.
    Sun SS; Guo XD; Li WD; Chen JL
    World J Clin Cases; 2024 Jan; 12(2):285-292. PubMed ID: 38313649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
    Ichida A; Arita J; Hatano E; Eguchi S; Saiura A; Nagano H; Shindoh J; Hashimoto M; Takemura N; Taura K; Sakamoto Y; Takahashi Y; Seyama Y; Sasaki Y; Uemura K; Kokudo N; Hasegawa K
    Liver Cancer; 2024 Jun; 13(3):322-334. PubMed ID: 38894811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
    Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
    Front Immunol; 2022; 13():944062. PubMed ID: 36091003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial.
    Guo C; Zhang J; Huang X; Chen Y; Sheng J; Huang X; Sun J; Xiao W; Sun K; Gao S; Que R; Shen Y; Zhang M; Wu J; Bai X; Liang T
    Hepatol Commun; 2023 Mar; 7(3):e0054. PubMed ID: 36757445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study.
    Zhang Q; Liu X; Wei S; Zhang L; Tian Y; Gao Z; Jin M; Yan S
    Front Oncol; 2021; 11():751391. PubMed ID: 34900698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
    Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
    Front Oncol; 2022; 12():909035. PubMed ID: 35712486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study.
    Yi Y; Sun BY; Weng JL; Zhou C; Zhou CH; Cai MH; Zhang JY; Gao H; Sun J; Zhou J; Fan J; Ren N; Qiu SJ
    Front Oncol; 2022; 12():1046584. PubMed ID: 36505772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.
    Ikeda M; Yamashita T; Ogasawara S; Kudo M; Inaba Y; Morimoto M; Tsuchiya K; Shimizu S; Kojima Y; Hiraoka A; Nouso K; Aikata H; Numata K; Sato T; Okusaka T; Furuse J
    Liver Cancer; 2024 Apr; 13(2):193-202. PubMed ID: 38751550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and/or Right Atrium.
    Ning S; Li X; Ma X; Liu J; Chang X
    J Hepatocell Carcinoma; 2023; 10():1511-1525. PubMed ID: 37724186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.